API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accesswire.com/720110/Aytu-BioPharma-Announces-Strategic-Shift-to-Focus-on-Commercial-Operations-and-Indefinite-Suspension-of-Clinical-Development-Programs
https://www.accesswire.com/712255/Aytu-BioPharma-Announces-Issuance-of-Its-First-Patent-for-AR101Enzastaurin
https://www.prnewswire.com/news-releases/denovo-biopharma-llc-announces-partner-aytu-biopharma-receives-fda-clearance-and-orphan-drug-designation-for-enzastaurin-in-vascular-ehlers-danlos-syndrome-301444292.html
https://www.prnewswire.com/news-releases/first-patient-dosed-in-biomarker-guided-phase-3-study-of-db102-enzastaurin-in-patients-with-newly-diagnosed-glioblastoma-gbm-301202417.html
https://www.prnewswire.com/news-releases/first-patient-dosed-in-pivotal-biomarker-guided-phase-3-study-of-first-line-therapy-with-db102-enzastaurin--r-chop-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-dlbcl-300623879.html